...BRCA1/2, PALB2, and NRG1 fusions) that offer potential targets for precision therapy. Bispecific antibodies, such as ant...
...BRCA1/BRCA2), (gBRCAm), who are typically young women, often require more aggressive therapeutic interventions. These mu...
...BRCA1/2 mutations. Despite initial response, clinical resistance rapidly develops, and few options exist as later-line t...
...BRCA1, BRCA2, and BAX, along with other apoptotic genes involved in tumorigenesis, apoptosis, and drug resistance. Targe...
...BRCA1/BRCA2 mutations. Two RE methylation clusters were identified. Cluster 1 exhibited a more hypomethylated RE profile...
...BRCA1/BRCA2 mutations), <40 years old at diagnosis, or history of breast cancer recurrence-were offered tumor-informed c...
...BRCA1 of a proband and her mother, both of whom had inconclusive conventional BRCA1/2 genetic test results, by targeted ...
...BRCA1/BRCA2 mutation, primary treatment, and surgical outcome are strong independent prognostic factors of overall survi...
...BRCA1) by signal recovery after removing a black hole quencher (BHQ) linked DNA, showing a wide linear range from 1.0 pM...
...BRCA1/2), and autophagy-related genes (e.g., CSNK2A1, BNIP3). Furthermore, emerging roles for long non-coding RNAs (lncR...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
